TB treatment: latest news

TB treatment resources

TB treatment features

TB treatment in your own words

TB treatment news from aidsmap

  • Early ART only increases TB IRIS risk for people with HIV who have a CD4 cell count below 50

    A low CD4 cell count increases the risk of immune reconstitution inflammatory syndrome (IRIS) for people starting antiretroviral therapy (ART) within two weeks of treatment for tuberculosis (TB), investigators report in the online edition of the Journal of Acquired ...

    28 November 2013 | Michael Carter
  • Rifampicin dose can be increased safely in TB treatment, may shorten duration

    Increasing the daily dose of rifampicin within the current TB treatment regimen from 10mg/kg to 15mg/kg and 20mg/kg did not result in an increased incidence of adverse events, according to findings from the RIFATOX trial presented at the 44th ...

    13 November 2013 | Mara Kardas-Nelson
  • Another negative result in the quest for a shorter TB treatment course

    Results from a Phase III trial that attempted to shorten the treatment duration for drug-sensitive pulmonary TB from four to six months, by using gatifloxacin instead of ethambutol, showed that the shortened treatment duration was inferior when compared to the ...

    11 November 2013 | Mara Kardas-Nelson
  • Simultaneous HIV and tuberculosis therapy doesn't cause problems with liver function

    Simultaneous treatment with anti-tuberculosis (TB) drugs and antiretroviral therapy (ART) does not result in major changes in liver function, investigators report in the International Journal of Infectious Diseases. Changes in liver function were monitored over twelve months in ...

    31 October 2013 | Michael Carter
  • Steroids reduce mortality risk for people taking TB treatment

    Corticosteroid treatment is associated with a reduced risk of mortality for people taking tuberculosis (TB) therapy, results of a meta-analysis published in The Lancet Infectious Diseases show. Treatment with steroids was associated with a significant 17% reduction in mortality risk, ...

    24 March 2013 | Michael Carter
  • Dosing of key TB drug rifampicin could go higher

    Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug levels may lead to a more rapid treatment response, allowing the treatment ...

    07 March 2013 | Keith Alcorn
  • Once-weekly continuation phase TB treatment equals standard of care

    A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St George’s University Medical School, London, told the 20th Conference on Retroviruses and ...

    07 March 2013 | Keith Alcorn
  • FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB

    Bedaquiline, the first agent in a new class of TB drug, has been recommended for accelerated approval by the Anti-Infective Drugs Advisory Committee of the United States Food and Drug Administration (FDA). The committee voted unanimously (18 to 0) ...

    03 December 2012 | Lesley Odendal
  • Risk of recurrence of active TB is high for people with HIV

    People living with HIV who have a history of active tuberculosis (TB) have a significant risk of the recurrence of the disease, investigators report in the online edition of Clinical Infectious Diseases. The risk of developing active TB ...

    22 October 2012 | Michael Carter
  • International study finds "worrying" levels of XDR-TB

    Results of an international study published in The Lancet show that 7% of people receiving second-line treatment for tuberculosis (TB) have extensively drug-resistant TB (XDR-TB). The investigators describe this finding as “worrying”. A total of 1278 people from eight countries were ...

    31 August 2012 | Michael Carter
More news

TB treatment news selected from other sources

More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also